1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
grants.nih.gov itself titles this page 'Expired RFA-NS-23-006' per Google search results; specific application due date could not be confirmed because the live page returned HTTP 403 to the fetcher (likely bot-blocking, not a broken URL).
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) HEAL Initiative (Multiple Institutes including NINDS, NIAMS, NCCIH, NIBIB, NIGMS).
This Small Business Innovation Research (SBIR) program funding opportunity aims to speed scientific solutions to the national opioid public health crisis by supporting the development of therapies and technologies for enhanced pain management. It focuses on improving pain measurement and treatment.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small business concerns. Supports research from early stage technology development through first in human demonstrations and early feasibility clinical studies. Confirm the full requirements in the official notice before applying.
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) HEAL Initiative (Multiple Institutes including NINDS, NIAMS, NCCIH, NIBIB, NIGMS). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article